While its activation in TAMs can reprogram them toward an anti-tumor M1 phenotype, its activation in ovarian cancer cells—via CXCL1, MIP-1β, MCP-1, TNF-α, and RANTES, or other secreted factors might be involved in driving metastasis, immune suppression, and therapy resistance. The gene discussed is CCL2; the disease is ovarian cancer.